Navigation Links
Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
Date:11/19/2007

AMSTERDAM, November 19 /PRNewswire/ -- Kiadis Pharma announced today that it has agreed to provide Rhitol during a limited period of time to requesting physicians participating in the ongoing phase I/II trial. The Rhitol phase I/II trial is closed for enrolment to treat new patients and is expected to complete at the end of this year. Kiadis Pharma anticipates applying for and starting a phase III study in 2008.

Manja Bouman, CEO Kiadis Pharma commented: "We realised that the sites participating in the ongoing phase II trial were left without treatment alternatives following the announcement of the enrolment closure. The interest these physicians show in using our product for new patients is very encouraging and we are very pleased that we can support them by providing Rhitol through special provisions, until the start of the phase III clinical trial."

The physicians interested in enabling new patients to receive treatment with Rhitol will obtain regulatory authorization from the appropriate agency to allow for compassionate use of Rhitol.

Rhitol is under development for patients with severe chronic steroid refractory Graft versus Host Disease (GvHD) who have exhausted other treatment options. Chronic GvHD is a condition that can develop after allogeneic bone marrow transplantation and resembles an autoimmune disease. The immune cells from the donor graft cause GvHD by attacking the patient's tissues and organs. There are two forms of GvHD: acute GvHD appears within 100 days after transplantation and chronic GvHD begins anytime after that period. Immune-suppressant drugs, such as steroids, are generally used to treat chronic GvHD. The disease can become a life-threatening condition when standard treatment cannot control its progression as the patient either does not respond to steroid treatment or develops severe side effects due to their use. Extensive chronic GvHD affects multiple organs and tissues and results in diminished quality of lif
'/>"/>

SOURCE Kiadis Pharma B.V.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Kiadis Pharma Announces ATIR Interim Clinical Results
2. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
3. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
4. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
10. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
11. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Strongly influenced by their self-interest, ... there are no consequences, researchers in Georgia State ... This could imply that humans are less concerned ... researchers said. Their findings are published in the ... of unfairness is affected by their self-interest, indicating ...
(Date:8/21/2014)... August 21, 2014 Local agencies in ... larger discounts for specific protection plans, according to released ... consumers to quote life insurance from local agencies using ... local agents that appear inside of the national system ... method of price reviews this year. Adults who enter ...
(Date:8/21/2014)... The “Proteomics Market by Technology (Protein ... Plasmon Resonance, X-ray Crystallography) - Instruments, Reagents & ... studies the major market drivers, restraints, and opportunities ... of the World (RoW) , Browse 138 market ... and in-depth TOC on “Proteomics Market by Technology ...
(Date:8/21/2014)... Vegas, NV (PRWEB) August 21, 2014 ... the Association for Packaging and Processing Technologies. They ... It’s the view into a whole new world ... of engaged attendees, interactive education, and the latest ... lifecycle solutions from exhibitors. This year at Pack ...
(Date:8/21/2014)... 21, 2014 Today, Zane Benefits, the ... the premium tax credits in 2015. , According to ... part of the Affordable Care Act (ACA), premium tax ... individual health insurance through the Health Insurance Marketplaces. , ... and the amount of the tax credits, updated for ...
Breaking Medicine News(10 mins):Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 2Health News:Influenced by Self-Interest, Humans Less Concerned About Inequity To Others, Researchers Find 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 5Health News:Absolute I&D Provides Discounted Labor for Pack Expo Chicago 2
... of U.S. patents, has expanded its free offerings, providing access ... host of other improvements, making it even easier to find and ... ... 9, 2008 -- PatentStorm , the searchable website of millions ...
... and lay the groundwork for Phase 2 trials ... Leukemia (AML) settings , , ... Pharmaceuticals today announced that a Phase 1 dose ... the recommended dose for Phase 2 studies and ...
... today that a total of,20 U.S. and global abstracts ... presentation at the 2008 San Antonio,Breast Cancer Symposium (SABCS) ... breast cancer to be presented on Sunday, December,14, by ... Two U.S. abstracts to be presented ...
... Dec. 9 Frost & Sullivan, a global ... recently held Manufacturing Summit, hosted the India Manufacturing ... Bangalore. Instituted in 2004, the awards aim to ... manufacturing capabilities and acknowledge the best facilities in ...
... an extended period of time when parents grappling with the natural grief ... 10 ways relatives and friends can make the holidays just a little ... Friends, the world,s largest self help support organization with more than 600 ... ...
... leading FDA software development company - provides medical device makers with ... technical report, available now. , ... (PRWEB) December 9, ... software development company Full Spectrum informs medical device ...
Cached Medicine News:Health News:PatentStorm Releases U.S. Patent Applications and Other Features 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 2Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 3Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 4Health News:Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting 5Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 2Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 3Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 2Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 3Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 4Health News:Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivan's India Manufacturing Excellence Awards 2008 5Health News:Ten Ways You Can Help a Family During the Holidays After a Child Dies 2Health News:Aimed at Medical Device Makers, FDA Software Development Company Full Spectrum Releases Free Technical Report on Software Protection Technology 2
(Date:8/21/2014)... Aug. 21, 2014 CVS Caremark Corporation (NYSE: ... Reference Yields and consideration payable in connection with its previously ... 7, 2014 for (1) any and all of its 6.250% ... (2) up to a maximum amount of its 6.125% Senior ... Senior Notes due 2017 (collectively, the "Maximum Tender Offer Notes" ...
(Date:8/21/2014)... HOUSTON , Aug. 21, 2014 ... innovation in paediatric medicine by awarding the three ... Paediatric Formulation initiative (EuPFI) conference . The ... 17 – 18 in Athens, Greece ... by pharmacy students and professionals, from which three ...
(Date:8/21/2014)... , Aug. 21, 2014   Royal Philips ... today announced it has received 510(k) clearance from ... its precision planning application for Transcatheter Aortic-Valve Implantation ... application provides interventionalists with pre-procedural, high-precision positioning to ... TAVI planning application is available as part of ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3
... MONICA, Calif., May 8, 2012 Reprints Desk, Inc., ... and first sale of its new mobile-web application ... iPads, mobile devices, product websites, and portals for ... Article Viewer for use by companies in Pharmaceuticals, Biotechnology, ...
... PHILADELPHIA, May 8, 2012  The new prescription sleep aid ... and only prescription sleep aid approved by the U.S. ... insomnia when a middle-of-the-night awakening is followed by difficulty ... four hours of bedtime remaining before the planned time ...
Cached Medicine Technology:Medical Reprints Deployment on iPads and Websites Made Easier with New ePrints Mobile-Web App from Reprints Desk 2Medical Reprints Deployment on iPads and Websites Made Easier with New ePrints Mobile-Web App from Reprints Desk 3Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 2Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 3Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 4Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 5Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV 6
... 2.0 is a reagent and probe system ... The high throughput plate based system is ... provides a unique approach for RNA detection ... using branched DNA (bDNA) technology. Branched DNA ...
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
QC 123 is an assayed quality control material for blood gas instrumentation. It is available in three (3) levels for monitoring analyzer performance at varying points within the clinical range....
...
Medicine Products: